OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. O'Neil Discusses the Current Treatment of Patients With CRC

March 28th 2018

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the current treatment of patients with colorectal cancer.

Dr. Trabulsi on Clinical Trial Combination Approaches in Prostate Cancer

March 28th 2018

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses clinical trials that are investigating combination approaches for patients with prostate cancer.

Dr. Pant on the Future of mCRC Treatment

March 28th 2018

Shubham Pant, MD, associate medical director of the Clinical & Translational Research Center, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing efforts in metastatic colorectal cancer (mCRC) and his hope for the future treatment landscape.

Dr. Donnellan Discusses Trials in Hematologic Malignancies

March 28th 2018

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses ongoing trials in hematologic malignancies.

Dr. Wakelee on Available Treatments Following Tumor Progression in Lung Cancer

March 27th 2018

Heather Wakelee, MD, associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses available treatment for patients with lung cancer who progress without a T790M mutation.

Dr. Naidoo on Studies of Immune-Related Adverse Events in Lung Cancer

March 27th 2018

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses studies investigating immune-related adverse events for patients with lung cancer.

Dr. Svensson on the Impact of PD-L1 Status in Gastric and Esophageal Adenocarcinoma

March 27th 2018

Maria Svensson, MD, Lund University, discusses the impact of determining PD-1 and PD-L1 status for patients with esophageal and gastric adenocarcinoma.

Dr. Winter Discusses the ZUMA-7 Trial in DLBCL

March 27th 2018

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the ZUMA-7 trial (NCT03391466) in diffuse large B-cell lymphoma (DLBCL).

Dr. Mittendorf Discusses Immunotherapy Efforts in Breast Cancer

March 27th 2018

Elizabeth A. Mittendorf, MD, PhD, Robert and Karen Hale Distinguished Chair in Surgical Oncology, director, Breast Immuno-Oncology Program, Director of Research, Breast Surgical Oncology, Dana-Farber/Brigham and Women’s Cancer Center, discusses immunotherapy efforts in breast cancer.

Dr. Postow Discusses New Targets in Melanoma

March 27th 2018

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses new targets in melanoma.

Dr. Leslie Discusses 2017 ASH Annual Meeting Updates

March 27th 2018

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses trial updates for patients with follicular lymphoma in the maintenance setting, which were presented at the 2017 ASH Annual Meeting.

Dr. Helft on the CAPTEM Regimen in Patients With Neuroendocrine Tumors

March 27th 2018

Paul R. Helft, MD, professor of medicine, Indiana University School of Medicine, Indiana University Health Melvin and Bren Simon Cancer Center, discusses the use of capecitabine and temozolomide across gastrointestinal (GI) neuroendocrine tumors.

Dr. Nanus Discusses Adjuvant Therapy for RCC

March 27th 2018

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses adjuvant therapy for patients with renal cell carcinoma.

Dr. Verma Discusses Biosimilars in the Oncology Sphere

March 27th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses biosimilars in the oncology sphere.

Dr. Goy Discusses Ibrutinib With Venetoclax in MCL

March 26th 2018

Andre Goy, MD, chairman and director, chief of Lymphoma, director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in the treatment of patients with mantle cell lymphoma (MCL).

Dr. Goldberg on Resistance to Osimertinib for NSCLC

March 26th 2018

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses resistance to first- or second-line osimertinib (Tagrisso) for patients with EGFR-mutated non–small cell lung cancer (NSCLC).

Dr. Kay Discusses the Role of Ibrutinib in CLL

March 26th 2018

Neil E. Kay, MD, professor of medicine, Mayo Clinic, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Landgren on the Use of Triplets Versus Quadruplets in Multiple Myeloma

March 26th 2018

C. Ola Landgren, MD, PhD, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses the superiority of 3-drug regimens and the next steps in the treatment of patients with multiple myeloma.

Dr. Hamlin on the Significance of the ZUMA-I Trial

March 26th 2018

Paul A. Hamlin, MD, chief, Basking Ridge Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the importance of the ZUMA-I trial results in the field of B-cell lymphoma.

Dr. Hussain on the Importance of Next-Generation Sequencing in Prostate Cancer

March 24th 2018

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Progessor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cncer Center, Northwestern University Feinberg School of Medicine, discusses the importance of next-generation sequencing in prostate cancer.